Carl Schmid discusses how the district court decision that HHS must require insurers to count copay assistance towards patient out-of-pocket costs helps to make prescription drugs more affordable and accessible for patients.

Carl Schmid discusses how the district court decision that HHS must require insurers to count copay assistance towards patient out-of-pocket costs helps to make prescription drugs more affordable and accessible for patients.
Carl Schmid discusses litigation victory for patients brought by the HIV+Hepatitis Policy Institute and diabetes groups in which the judge struck down the federal rule allowing insurers to not count copay assistance toward patient out-of-pocket costs.
Carl Schmid discusses NC Blue Cross Blue Shield’s decision to remove HIV drugs from the highest and costliest drug tiers following a discrimination complaint filed by the HIV+Hepatitis Policy Institute and NC AIDS Action Network.
Carl Schmid and Kevin Herwig offer updates at USCHA on Braidwood v Becerra, which challenges ACA’s preventive services coverage requirement, and discuss the amicus brief filed by HIV+Hepatitis Policy Institute and supported by 24 HIV and hepatitis organizations and other amici briefs filed by other groups.
At the NAIC meeting, Carl Schmid and colleagues present consumer representatives’ report on investigation of how insurers are implementing ACA preventive service requirements, including PrEP, and urge state regulators to take action to ensure insurers are compliant with the law.